Cargando…
Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data
PURPOSE: During preclinical testing, teriparatide caused a dose‐dependent increase in the incidence of osteosarcoma in rats. This study compared the incidence rate of osteosarcoma among patients aged ≥65 years treated with teriparatide vs a matched‐comparator cohort. METHODS: This population‐based c...
Autores principales: | Gilsenan, Alicia, Midkiff, Kirk, Harris, David, McQuay, Lisa, Hunter, Shannon, Kellier‐Steele, Nicole, Andrews, Elizabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754479/ https://www.ncbi.nlm.nih.gov/pubmed/32894794 http://dx.doi.org/10.1002/pds.5103 |
Ejemplares similares
-
Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15‐Year US Postmarketing Surveillance Study
por: Gilsenan, Alicia, et al.
Publicado: (2020) -
Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates
por: Krege, John H, et al.
Publicado: (2022) -
The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years
por: Andrews, Elizabeth B, et al.
Publicado: (2012) -
The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years
por: Gilsenan, A., et al.
Publicado: (2018) -
Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study
por: Gilsenan, A., et al.
Publicado: (2020)